Fusion Antibody for Alzheimer's Disease with Bidirectional Transport Across the Blood−Brain Barrier and Aβ Fibril Disaggregation
- 22 February 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 18 (2), 447-455
- https://doi.org/10.1021/bc060349x
Abstract
Delivery of monoclonal antibody therapeutics across the blood−brain barrier is an obstacle to the diagnosis or therapy of CNS disease with antibody drugs. The immune therapy of Alzheimer's disease attempts to disaggregate the amyloid plaque of Alzheimer's disease with an anti-Aβ monoclonal antibody. The present work is based on a three-step model of immune therapy of Alzheimer's disease: (1) influx of the anti-Aβ monoclonal antibody across the blood−brain barrier in the blood to brain direction, (2) binding and disaggregation of Aβ fibrils in brain, and (3) efflux of the anti-Aβ monoclonal antibody across the blood−brain barrier in the brain to blood direction. This is accomplished with the genetic engineering of a trifunctional fusion antibody that binds (1) the human insulin receptor, which mediates the influx from blood to brain across the blood−brain barrier, (2) the Aβ fibril to disaggregate amyloid plaque, and (3) the Fc receptor, which mediates the efflux from brain to blood across the blood−brain barrier. This fusion protein is a new antibody-based therapeutic for Alzheimer's disease that is specifically engineered to cross the human blood−brain barrier in both directions.Keywords
This publication has 34 references indexed in Scilit:
- Recombinant approaches to IgG-like bispecific antibodiesActa Pharmacologica Sinica, 2005
- Changes in the Arterial Fraction of Human Cerebral Blood Volume during Hypercapnia and Hypocapnia Measured by Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 2005
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002
- Mediated efflux of IgG molecules from brain to blood across the blood–brain barrierJournal of Neuroimmunology, 2001
- An efficient route to human bispecific IgGNature Biotechnology, 1998
- Design and production of novel tetravalent bispecific antibodiesNature Biotechnology, 1997
- Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrierJournal of Neurocytology, 1995
- The Intracellular Component of Cellular 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide (MTT) Reduction Is Specifically Inhibited by β‐Amyloid PeptidesJournal of Neurochemistry, 1995
- Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma ProteinsJournal of Neurochemistry, 1990
- Human Blood—Brain Barrier Insulin ReceptorJournal of Neurochemistry, 1985